FINAL PROGRAM - Society for Immunotherapy of Cancer
FINAL PROGRAM - Society for Immunotherapy of Cancer
FINAL PROGRAM - Society for Immunotherapy of Cancer
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Poster Listings<br />
71<br />
ARGINASE 2 AND INOS EXPRESSION AS<br />
POTENTIAL PROGNOSTIC AND PREDICTIVE<br />
BIOMARKERS OF SURVIVAL IN RENAL CELL<br />
CARCINOMA<br />
David J. Tate 1 , John R. Patterson 1 , Luis Marrero 1 , Luis DelValle 1 ,<br />
Benjamin R. Lee 2 , Marc S. Ernst<strong>of</strong>f 3 , Arnold H. Zea 1<br />
1<br />
Stanley S. Scott <strong>Cancer</strong> Center, LSUHSC, New Orleans, LA<br />
2<br />
Urology, Tulane University, New Orleans, LA<br />
3<br />
Hematology/Oncology, Dartmouth-Hitchcock Medical Center,<br />
Lebanon, NH<br />
72<br />
VALIDATION OF ELISPOT ASSAYS IN 384 WELL<br />
FORMAT - 400 TESTS DONE WITH 10 ML BLOOD<br />
Jodi Hanson, Richard Caspell, Paul V. Lehmann, Wenji Zhang<br />
CTL (Cellular Technology Ltd.), Shaker Heights, OH<br />
73<br />
DOES OVERNIGHT RESTING REALLY ENHANCE<br />
THE PERFORMANCE OF ELISPOT ASSAYS?<br />
Richard Caspell, Helena Batoulis, Mascha S. Recks, Edith Karacsony,<br />
Jodi Hanson, Stephanie Kürten, Paul V. Lehmann, Wenji Zhang<br />
CTL (Cellular Technology Ltd.), Shaker Heights, OH<br />
IMMUNOLOGY OF CANCER STEM CELLS<br />
AND EPITHELIAL-TO-MESENCHYMAL<br />
TRANSITION (EMT)<br />
74<br />
FIBROBLAST GROWTH FACTOR-1 INDUCES<br />
PRIMARY EPITHELIAL TUMOR CELL PLASTICITY<br />
TOWARD A MESENCHYMAL-LIKE PHENOTYPE<br />
Katie A. Palen, James J. Weber, Bryon D. Johnson, Jill A. Gershan<br />
Pediatrics, Medical College <strong>of</strong> Wisconsin, Milwaukee, WI<br />
75<br />
PRECLINICAL EVALUATION OF WITHAFERIN A<br />
AS AN ANTI-CANCER STEM CELL AGENT USING A<br />
UNIQUE HUMAN UP-LN1 CARCINOMA CELL LINE<br />
WITH CANCER STEM CELL PROPERTIES<br />
Chi-Tai Yeh 1,2 , Alexander T. Wu 3,4 , Hung-Chang Chen 5 , Shuen-Kuei<br />
Liao 5<br />
1<br />
Graduate Institute <strong>of</strong> Clinical Medicine, School <strong>of</strong> Medicine, College <strong>of</strong><br />
Medicine, Taipei Medical University, Taipei, Taiwan<br />
2<br />
<strong>Cancer</strong> Center, Taipei Medical University-Shuang Ho Hospital, Taipei,<br />
Taiwan<br />
3<br />
Department <strong>of</strong> Radiation, School <strong>of</strong> Medicine, College <strong>of</strong> Medicine,<br />
Taipei Medical University, Taipei, Taiwan<br />
4<br />
Translational Research Laboratory, <strong>Cancer</strong> Center, Taipei Medical<br />
University Hospital, Taipei, Taiwan<br />
5<br />
Taipei Medical University Hospital, Taipei, Taiwan<br />
76<br />
NATURALLY OCCURRING IMMUNE RESPONSES<br />
AGAINST SOX2 AND BCL-2 IN PATIENTS WITH<br />
ADVANCED AND EARLY-STAGE CANCER<br />
Juan Marquez 1,2 , Erik Ramos 2,1,3 , Pedro Lucero 1 , Alejandro Camacho<br />
Hernandez 1 , Ramon Cabello 1 , Murray B. Gardner 4 , Brandon Toney 3 ,<br />
Megan Maurano 3 , Jose V. Torres 3 , Fernando A. Durazo Bustamante 1,3<br />
1<br />
Clinical Tumor Immunology, Sonora <strong>Cancer</strong> Research Center, Ciudad<br />
Obregon, Mexico<br />
2<br />
Escuela de Medicina, Universidad Xochicalco, Ensenada, Mexico<br />
3<br />
Medical Microbiology and Immunology, University <strong>of</strong> Cali<strong>for</strong>nia Davis,<br />
Davis, CA<br />
4<br />
Comparative Pathology, University <strong>of</strong> Cali<strong>for</strong>nia Davis, Davis, CA<br />
IMMUNOTHERAPY COMBINATIONS<br />
77<br />
AUTOLOGOUS VACCINE AHICE, THERAPY RESULTS<br />
Hannes Anthopoulos 1 , Karl-Heinz Regele 2<br />
1<br />
Vaccine Production, K-BIO Institute <strong>for</strong> Cellbiotechnology and<br />
Immunology GmbH, Groebenzell, Germany<br />
2<br />
Vaccine Application, <strong>Immunotherapy</strong>, K-BIO Institute <strong>for</strong><br />
Cellbiotechnology and Immunology GmbH, Groebenzell, Germany<br />
78<br />
PARTIAL CD4-DEPLETION ENHANCES THE<br />
EFFICACY OF MULTIPLE VACCINATIONS<br />
Sarah E. Church 1,2 , Shawn M. Jensen 1 , Bernard A. Fox 1,2<br />
1<br />
Robert W Franz <strong>Cancer</strong> Research Center, Earle A Chiles Research<br />
Institute, Portland, OR<br />
2<br />
Molecular Microbiology and Immunology, Oregon Health and Science<br />
University, Portland, OR<br />
79<br />
T-CELL IMMUNITY IN HEPATOCELLULAR<br />
CARCINOMA AGAINST THE WILMS’ TUMOR<br />
PROTEIN-1 (WT1) AS A POTENTIAL TARGET<br />
STRUCTURE FOR IMMUNOTHERAPEUTIC<br />
APPROACHES<br />
Susanne Doering 1 , Katja Klugewitz 2 , David Stather 1 , Daniel Seeh<strong>of</strong>er 4 ,<br />
Andreas Pascher 4 , Severin Daum 2 , Peter Neuhaus 4 , Martin Zeitz 2 ,<br />
Eckhard Thiel 1 , Ulrich Keilholz 1 , Carmen Scheibenbogen 3 , Rajan<br />
Somasundaram 2 , Anne Letsch 1<br />
1<br />
Hematology, Oncology and Transfusion Medicine, Charite University<br />
CBF, Berlin, Germany<br />
2<br />
Gastroenterology, Infectious Diseases and Rheumatology, Charite<br />
University CBF, Berlin, Germany<br />
3<br />
Medical Immunology, Charite University CCM, Berlin, Germany<br />
4<br />
General, Visceral and Transplantation Surgery, Charite University CVK,<br />
Berlin, Germany<br />
ABSTRACTS AND<br />
POSTER LISTINGS<br />
<strong>FINAL</strong> <strong>PROGRAM</strong> • SITC 26 TH ANNUAL MEETING<br />
November 4-6, 2011 • North Bethesda, MD • www.sitcancer.org<br />
65
Change language